Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 399

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 399
---
                                                                                          |

| (9) | Represents (a) 1,458,263 shares of Common Stock held directly and (b) 14,018 shares underlying the Private                                                                                                                                               
 Warrants held by SCLX JV, all of which are currently exercisable, in each case, transferred to SCLX JV in connection with the Equity Repurchase Transaction. Does not include any shares of Series A Preferred Stock. SCLX JV holds 490,617 Private      
 Warrants. In connection with the Reverse Stock Split, the SPAC Warrants (which include the Private Warrants) were adjusted in accordance with their terms such that the number of SPAC Warrants outstanding was unchanged, but each SPAC Warrant now     
 entitles the holder to purchase 1/35th of a share of Common Stock at an exercise price of $402.50 per whole share (provided that in no event shall the holder of any such warrants be entitled, upon the exercise of such warrants, to receive a         
 fractional interest in a share of Common Stock upon such exercise and the Company shall, upon such exercise, round up to the nearest whole number of shares of Common Stock to be issued to such holder). Accordingly, the Private Warrants held by SCLX 
 JV are currently exercisable for 14,018 shares of Common Stock. The voting and dispositive power of the equity securities of the Company (including the Series A Preferred Stock) held by SCLX JV are subject to the control of an independent manager,  
 Xiao Xu, until such time as the Oramed Note and any Additional Notes are paid in full. The business address of SCLX Stock Acquisition JV LLC is 960 San Antonio Road, Palo Alto, CA 94303.                                                               |

| (10) | Represents 350,000 shares of Common Stock held directly and 382,717 shares underlying certain warrants to                                                                                                                                      
 purchase Common Stock, with an exercise price of $0.01 per share, held by Oramed exercisable within 60 days of March 31, 2025. Such warrants held by Oramed are subject to a 9.99% beneficial ownership limitation and the number of shares of 
 Common Stock set forth in the table above give effect to such limitation. The foregoing ownership information for Oramed is based on information supplied by Oramed in a statement on Schedule 13G filed with the SEC on January 17, 2025 that 
 reports its sole voting power and sole dispositive power and